Search
Semaglutide Treatment Options for Type 2 Diabetes
A collection of 95 research studies in Type 2 Diabetes where Semaglutide is the interventional treatment. Semaglutide is used for conditions such as Type 2 Diabetes.
25 - 36 of 95
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Type 2 Diabetes
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Diabetic Peripheral Neuropathy Clinical Study (Raleigh)
Recruiting
If you struggle with chronic nerve pain in your legs due to diabetes (diabetic peripheral neuropathy, or DPN), Vertex Pharmaceuticals is conducting research studies that may be an option.
Conditions:
Diabetic Peripheral Neuropathy
Diabetes
Type 2 Diabetes
Featured Trial
Diabetic Peripheral Neuropathy Clinical Study
Recruiting
If you struggle with chronic nerve pain in your legs due to diabetes (diabetic peripheral neuropathy, or DPN), Vertex Pharmaceuticals is conducting research studies that may be an option.
Conditions:
Diabetes
Diabetes Mellitus
Type 2 Diabetes
Diabetes Mellitus
Type 1
Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data
Active Not Recruiting
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Emulation of the SOUL Diabetes Trial in Healthcare Claims
Completed
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/21/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2
Emulating the PIONEER6 Diabetes Trial Using Healthcare Claims
Completed
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/21/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2
Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction
Active Not Recruiting
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction
Active Not Recruiting
This cohort study aims to assess the comparative effectiveness of tirzepatide versus semaglutide with respect to cardiovascular events in patients with type 2 diabetes and heart failure with preserved ejection fraction.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Type 2 Diabetes, Heart Failure
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
Recruiting
The purpose of this study is to understand the role of GLP-1 in the pathogenesis of T2D in youth and explore their potential salutary effects and ability to delay the progressive loss of ß-cell function and reduce hepatic steatosis in youth with prediabetes/new onset T2D and NAFLD.
Gender:
ALL
Ages:
Between 10 years and 21 years
Trial Updated:
05/15/2025
Locations: Pediatric Diabetes Center, New Haven, Connecticut
Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab
Recruiting
The goal of this study is to determine how a drug class called glucagon-like peptide-1 receptor agonists (GLP-1Ra) affects people during an early stage of Type 1 Diabetes undergoing clinical teplizumab treatment. This study involves giving participants a liquid meal under different conditions and observing how their bodies respond, focusing on blood sugar levels, insulin effectiveness, and blood vessel function. The meal tests are followed by two post-treatment tests, one with the GLP-1Ra drug a... Read More
Gender:
ALL
Ages:
Between 12 years and 50 years
Trial Updated:
05/13/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Type 1 Diabetes
Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
Recruiting
More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. GLP-1 analogues are anti-obesity medications that are cardioprotective in adults with type 2 diabetes, however evaluation of these agents in people with T1D has been limited to glycemic outcomes. Investigators aim to study the impact of GLP-1 analogue obesity treatment on markers of cardiometabolic risk in young adults with T1D and... Read More
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
04/29/2025
Locations: Yale Pediatric Diabetes Center, Adult and Children's Progam, New Haven, Connecticut
Conditions: Diabetes type1, Obesity
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
Recruiting
The goal of this research study is to evaluate the pathophysiologic mechanisms by which genetic variation impacts response to an FDA-approved medication commonly used to treat type 2 diabetes called oral semaglutide (Rybelsus) and to characterize the physiological response to a mixed meal tolerance test (MMTT) before and after a 14-day treatment with oral semaglutide. The investigators will do this by measuring factors in the blood, such as sugars, fats, metabolites, and proteins, after eating a... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/28/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Genetic Predisposition, Metabolic Diseases, Type 2 Diabetes
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Active Not Recruiting
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: University of Alabama - Department of Nutrition Sciences, Birmingham, Alabama +76 locations
Conditions: Diabetes Mellitus, Type 2
Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults
Completed
Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.
Gender:
ALL
Ages:
Between 65 years and 90 years
Trial Updated:
04/22/2025
Locations: UT Health San Antonio, San Antonio, Texas
Conditions: Aging, Diabetes Mellitus, Type 2, PreDiabetes, Overweight and Obesity
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Active Not Recruiting
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Absolute Clinical Research, Phoenix, Arizona +130 locations
Conditions: Type 2 Diabetes
25 - 36 of 95